Oncology Data Advisor

i3 Health

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

  1. EXPIRING SOON! Mitigating Disease Burden and Healthcare Disparities in Multiple Myeloma

    2D AGO

    EXPIRING SOON! Mitigating Disease Burden and Healthcare Disparities in Multiple Myeloma

    Last Chance: Multiple Myeloma Task Force Podcast Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025. Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma. Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

    33 min
  2. Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

    AUG 11

    Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

    Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now! Click here to claim credit for this activity: https://bit.ly/3HtOziO Click here to listen to Module 1 of this series: https://bit.ly/45u106o

    27 min
  3. Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

    AUG 11

    Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

    Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now! Click here to claim you CE credit for this activity: https://bit.ly/45u106o Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

    26 min
  4. Additional Advances in Genetic Counseling and Testing in Cancer Care With Filipa Lynce, MD, and Catherine Skefos, MA, MS, CGC

    AUG 7

    Additional Advances in Genetic Counseling and Testing in Cancer Care With Filipa Lynce, MD, and Catherine Skefos, MA, MS, CGC

    Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians. Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX

    13 min
  5. Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 2

    AUG 7

    Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 2

    i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity! Click below to complete the claim your CE credit: Module 2: https://bit.ly/405xEJO Click below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing Recommendations Module 1: https://bit.ly/49NCaQu

    24 min
  6. Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 1

    AUG 7

    Additional Advances in HER2-Mutated NSCLC With Julia Kathleen Rotow, MD + Activity Module 1

    i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity! Click below to complete the claim your CE credit: Module 1: https://bit.ly/49NCaQu Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC Module 2: https://bit.ly/405xEJO

    25 min
  7. Unmasking Hereditary ATTR-CM: A Webinar Preview With Mathew Maurer, MD

    JUL 28

    Unmasking Hereditary ATTR-CM: A Webinar Preview With Mathew Maurer, MD

    oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM. In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration. Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here: bit.ly/3UgV7nF

    9 min
  8. Multicancer Early Detection: A Fellow’s Perspective With Waqas Haque, MD, MPH

    JUL 25

    Multicancer Early Detection: A Fellow’s Perspective With Waqas Haque, MD, MPH

    Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. Click the links below for the full CME activity! Module 1: https://bit.ly/3X8apxa Module 2 : https://bit.ly/41rS14I Module 3: https://bit.ly/4b9JU00 And view the slide decks here: Module 1: https://bit.ly/4l0NTzc Module 2: https://bit.ly/4fdXwti Module 3: https://bit.ly/40AkmoP

    15 min
See All (423)

Ratings & Reviews

4.4
out of 5
12 Ratings

About

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Information

  • Creator
    i3 Health
  • Years Active
    2014 - 2025
  • Episodes
    423
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    Oncology Data Advisor

You Might Also Like